AbbVie gets CHMP opinion recommending marketing authorization of epcoritamab

AbbVie announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending the conditional marketing authorization of epcoritamab, the first and only T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more prior therapies. The European Commission decision on this indication for epcoritamab is anticipated later this year.